Valuation: GENFIT

Market Cap 679M 779M 634M 583M 1.09B 74.53B 1.12B 7.51B 2.94B 36.97B 2.93B 2.86B 127B P/E 2026 *
35x
P/E 2027 * 90.2x
Enterprise Value 628M 720M 586M 539M 1.01B 68.92B 1.04B 6.95B 2.72B 34.19B 2.71B 2.65B 118B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 4.94x
Free-Float
86.88%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week-3.55%
Current month+24.19%
1 month+38.58%
3 months+61.99%
6 months+134.11%
Current year+148.62%
1 week 13.04
Extreme 13.04
13.48
1 month 10.18
Extreme 10.18
14.02
Current year 5.08
Extreme 5.075
14.02
1 year 3.01
Extreme 3.006
14.02
3 years 2.8
Extreme 2.8
14.02
5 years 2.74
Extreme 2.74
14.02
10 years 2.74
Extreme 2.74
33.76
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-3.55% - - 752M
+2.61%+1.91%+1.70%+13.91% 47.88B
-1.60%-1.29%+385.56%+603.70% 39.09B
-0.98%+2.68%+11.10%+45.34% 36.75B
+1.90%+22.79%+25.18%+9.47% 40.55B
+1.47%+4.90%+6.48%+43.52% 27.96B
-0.94%-1.23% - - 16.77B
+2.44%+10.02%+29.11%+129.56% 15.94B
+0.18%-1.46%+4.92%+10.14% 13.55B
-1.14%+6.94%-6.05%-29.33% 13.81B
Average +0.07%+4.66%+57.25%+103.29% 28.03B
Weighted average by Cap. +0.60%+5.06%+73.07%+124.52%

Financials

2026 *2027 *
Net sales 100M 115M 93.48M 85.95M 161M 10.99B 165M 1.11B 433M 5.45B 432M 422M 18.77B 124M 142M 116M 106M 200M 13.61B 204M 1.37B 536M 6.75B 534M 522M 23.24B
Net income 22.88M 26.23M 21.34M 19.62M 36.82M 2.51B 37.7M 253M 98.9M 1.25B 98.53M 96.35M 4.29B 6.8M 7.8M 6.34M 5.83M 10.94M 746M 11.21M 75.22M 29.39M 370M 29.28M 28.64M 1.27B
Net Debt -51.12M -58.61M -47.69M -43.85M -82.27M -5.61B -84.23M -565M -221M -2.78B -220M -215M -9.57B -66.17M -75.87M -61.74M -56.76M -106M -7.26B -109M -732M -286M -3.6B -285M -279M -12.4B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change
29/07/26 €13.04 -3.26%
28/07/26 €13.48 +0.45%
27/07/26 €13.42 +2.44%
24/07/26 €13.10 0.00%
23/07/26 €13.10 -6.56%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.58EUR
Average target price
15.90EUR
Spread / Average Target
+17.08%

Quarterly revenue - Rate of surprise